Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Gilead Sciences Inc GILD

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.


NDAQ:GILD - Post by User

Bullboard Posts
Post by Carlos66on Jan 28, 2016 10:38am
70 Views
Post# 24501378

future is dim

future is dim
First it was Hiliary, Bernie Sanders, then the Republicans joined in & finally yesterday the AG of Mass. jumped on the bandwagon in bashing the pharma sector about pricing policies.
See this excerpt from the AG of Mass. website....

The headquarters of Gilead Sciences in Foster City, Calif.
Eric Risberg | AP
The headquarters of Gilead Sciences in Foster City, Calif.

Massachusetts Attorney General Maura Healey has warned Gilead Sciences that it could face legal action if it doesn't reduce the prices of its Sovaldi and Harvoni medications.

In a letter to Gilead CEO John Martin, Healey suggested the costs of the two hepatitis C drugs "may constitute an unfair trade practice in violation of Massachusetts law."

"I write to encourage you to reconsider Gilead's pricing structure for Sovaldi and Harvoni ... so that we may actually see this infectious disease eradicated in the United States in our lifetime," she wrote, adding that her office will "continue to examine this potential claim for unfair commercial conduct."

A full course of Sovaldi currently goes for $84,000, and a 12-week Harvoni treatment costs $94,500.

Healey wrote in her letter date Friday that that if Massachusetts were to purchase Sovaldi at its retail price for all of the people with hepatitis C in the state's prisons, then the costs would "easily exceed" the entire budget for prisoner health care.

After word of the price increases for specialty drugs including Sovaldi, Democratic presidential hopeful Hillary Clinton announced she planned take action against skyrocketing drug costs.

Gilead has said it is committed to expand access to its medicines, regardless of ability to pay. The company has said it offers a "support path" for those who may have trouble paying for its therapies.

"We agree with the Attorney General about the importance of helping all HCV patients — and that the advent of safe, effective regimens means we can now consider the possibility of eradicating the disease," a Gilead spokeswoman told CNBC, adding that the company had reached out to Healey about setting up a meeting to discuss the issue.

"We look forward to working with the Attorney General's office to address questions and concerns and ensure a mutual understanding of the work we are doing to deliver a cure for HCV to as many patients as possible in Massachusetts and around the world," she added.

IMO....GILD must discover something this year & get into clinical trials in the 1stQ 2017.

CNBC commented on GILD's future....'what does GILD have in the pipeline to replace Sovaldi etc.? Nothing'

carlos

Bullboard Posts